Hely Shah, MD
Medical Oncology · Ukiah, CANPI 1912770660
Payments from drug & device makers
Across 64 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$128
- E.r. Squibb & Sons, L.L.C.$111
- Novartis$111
- AbbVie$103
- Ipsen Biopharmaceuticals, Inc$96
- Sanofi$86
- plus $1K from 25 others
What the payments were for
- Food & beverage$1,60095%
- Education$795%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 5 | $128 |
| E.r. Squibb & Sons, L.L.C. | 5 | $111 |
| Novartis | 5 | $111 |
| AbbVie | 4 | $103 |
| Ipsen Biopharmaceuticals, Inc | 4 | $96 |
| Sanofi | 3 | $86 |
| Myriad Genetic Laboratories, Inc. | 3 | $79 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Merck | 3 | $70 |
| Genentech USA, Inc. | 3 | $70 |
| Deciphera Pharmaceuticals Inc. | 1 | $62 |
| Array Biopharma Inc | 2 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Bristol Myers Squibb | 2 | $48 |
| Gilead | 2 | $48 |
| Pfizer | 2 | $47 |
| Astellas Pharma US Inc | 2 | $43 |
| Johnson & Johnson | 1 | $42 |
| Lilly USA, LLC | 2 | $41 |
| Rigel Pharmaceuticals, Inc. | 1 | $38 |
| Boehringer Ingelheim | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Taiho Oncology, Inc. | 1 | $29 |
| Novocure Inc. | 1 | $26 |
| Springworks Therapeutics, Inc. | 1 | $26 |
| GSK | 1 | $25 |
| EMD Serono, Inc. | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Fennec Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Beigene USA, Inc. | 1 | $14 |
How this compares
$1,679 in reported general payments places this provider in the 25th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 15 | $255 |
| Ondansetron Hcl | 18 | $174 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $143 |
| Hydromorphone Hcl | 14 | $89 |
| Prednisone | 23 | $82 |
| Pantoprazole Sodium | 14 | $59 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Ukiah
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Farshid DayyaniOrange$13.4M
- Daneng LiDuarte$12.4M
- Heinz-Josef LenzLos Angeles$11.6M
- Kevin KimSan Francisco$10.8M
- Anthony El-KhoueiryLos Angeles$10.5M
- Amy ChienSan Francisco$10.5M
- Sandhya SrinivasStanford$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.